DYN Logo

Dyne Therapeutics Inc (DYN) Stock Forecast & Price Prediction

Live DYN Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$13.91

-0.14 (-1.00%)

12 Month Price Forecast For DYN

$13.91
Current Price
$1.42B
Market Cap
12 Ratings
Buy 11
Hold 1
Sell 0
Wall St Analyst Ratings

Distance to DYN Price Forecasts

+374.5%
To High Target of $66.00
+259.5%
To Median Target of $50.00
+29.4%
To Low Target of $18.00

DYN Price Momentum

-9.5%
1 Week Change
-10.5%
1 Month Change
-41.1%
1 Year Change
-41.0%
Year-to-Date Change
-70.7%
From 52W High of $47.45
+6.4%
From 52W Low of $13.07

๐Ÿค” Considering Dyne Therapeutics (DYN)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 15, 2025 1:49 PM UTC

DYN Analyst Ratings & Price Targets

Based on our analysis of 12 Wall Street analysts, DYN has a bullish consensus with a median price target of $50.00 (ranging from $18.00 to $66.00). Currently trading at $13.91, the median forecast implies a 259.5% upside. This outlook is supported by 11 Buy, 1 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Paul Matteis at Stifel, projecting a 374.5% upside. Conversely, the most conservative target is provided by Tessa Romero at JP Morgan, suggesting a 29.4% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

DYN Analyst Consensus

11
Buy
1
Hold
0
Sell

DYN Price Target Range

Low
$18.00
Average
$50.00
High
$66.00
Current: $13.91

Latest DYN Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for DYN.

Date Firm Analyst Rating Change Price Target
Jan 24, 2025 Guggenheim Debjit Chattopadhyay Buy Reiterates $0.00
Jan 14, 2025 RBC Capital Luca Issi Outperform Reiterates $45.00
Jan 13, 2025 HC Wainwright & Co. Andrew Fein Buy Reiterates $55.00
Jan 10, 2025 HC Wainwright & Co. Andrew Fein Buy Reiterates $55.00
Jan 10, 2025 Chardan Capital Keay Nakae Buy Maintains $50.00
Dec 13, 2024 Baird Outperform Initiates $0.00
Nov 26, 2024 RBC Capital Luca Issi Outperform Initiates $45.00
Nov 13, 2024 Chardan Capital Keay Nakae Buy Maintains $50.00
Nov 13, 2024 HC Wainwright & Co. Andrew Fein Buy Reiterates $55.00
Oct 24, 2024 JP Morgan Tessa Romero Neutral Downgrade $35.00
Sep 23, 2024 Piper Sandler Edward Tenthoff Overweight Reiterates $53.00
Sep 4, 2024 HC Wainwright & Co. Andrew Fein Buy Reiterates $55.00
Sep 3, 2024 Oppenheimer Francois Brisebois Outperform Reiterates $55.00
Aug 16, 2024 Stifel Paul Matteis Buy Maintains $66.00
Aug 15, 2024 Guggenheim Debjit Chattopadhyay Buy Maintains $50.00
Aug 14, 2024 Morgan Stanley Michael Ulz Overweight Maintains $52.00
Aug 13, 2024 Piper Sandler Edward Tenthoff Overweight Maintains $53.00
Aug 13, 2024 HC Wainwright & Co. Andrew Fein Buy Maintains $55.00
Jul 9, 2024 JP Morgan Tessa Romero Overweight Maintains $43.00
May 21, 2024 Chardan Capital Keay Nakae Buy Maintains $42.00

Stocks Similar to Dyne Therapeutics Inc

The following stocks are similar to Dyne Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Dyne Therapeutics Inc (DYN) Financial Data

Dyne Therapeutics Inc has a market capitalization of $1.42B with a P/E ratio of -3.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -68.7%.

Valuation Metrics

Market Cap $1.42B
Enterprise Value $716.75M
P/E Ratio -3.5x
PEG Ratio -4.4x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +51.1%
Current Ratio 17.0x
Debt/Equity 3.5x
ROE -68.7%
ROA -40.4%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Dyne Therapeutics Inc logo

Dyne Therapeutics Inc (DYN) Company Overview

About Dyne Therapeutics Inc

What They Do

Develops therapeutics for muscle diseases.

Business Model

The company operates as a biotechnology firm, focusing on developing a portfolio of therapeutics specifically for genetically driven muscle diseases. It generates revenue by advancing its clinical programs and potentially monetizing its therapeutic developments through partnerships, licensing agreements, or product sales once they receive regulatory approval.

Additional Information

Dyne Therapeutics utilizes its proprietary FORCE platform to deliver disease-modifying therapeutics aimed at conditions like myotonic dystrophy type 1 and Duchenne muscular dystrophy. Founded in 2017 and based in Waltham, Massachusetts, the company is positioned in a niche market with significant unmet medical needs.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

173

CEO

Mr. John G. Cox M.B.A.

Country

United States

IPO Year

1993

Dyne Therapeutics Inc (DYN) Latest News & Analysis

DYN stock latest news image
Quick Summary

Dyne Therapeutics (Nasdaq: DYN) will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 4:00 p.m. ET.

Why It Matters

Dyne Therapeutics' presentation at a major healthcare conference could signal advancements in their drug development, potentially influencing stock performance and investor sentiment in the biotech sector.

Source: GlobeNewsWire
Market Sentiment: Neutral
DYN stock latest news image
Quick Summary

The Zacks Medical-Drugs industry is experiencing peak innovation, with CORT, AMRX, DYN, NKTR, and CRDL suggested as potential portfolio additions.

Why It Matters

Innovation in the Zacks Medical-Drugs industry indicates potential growth and profitability for companies like CORT, AMRX, DYN, NKTR, and CRDL, which may enhance investment portfolios.

Source: Zacks Investment Research
Market Sentiment: Neutral
DYN stock latest news image
Quick Summary

Dyne Therapeutics (DYN) is now technically oversold, suggesting reduced selling pressure. Analysts are revising earnings estimates higher, indicating a potential trend reversal.

Why It Matters

Dyne Therapeutics' oversold status and analysts' upgraded earnings estimates suggest a potential rebound, signaling a favorable buying opportunity for investors.

Source: Zacks Investment Research
Market Sentiment: Positive
DYN stock latest news image
Quick Summary

Dyne Therapeutics, Inc. plans to submit for U.S. Accelerated Approval in the first half of 2026.

Why It Matters

Dyne Therapeutics' plan for U.S. Accelerated Approval signals potential for expedited market access and revenue growth, impacting stock performance and investor sentiment.

Source: GlobeNewsWire
Market Sentiment: Neutral
DYN stock latest news image
Quick Summary

Dyne Therapeutics, Inc. (DYN) announced new data from its Phase 1/2 ACHIEVE trial of DYNE-101 for myotonic dystrophy type 1 (DM1) on Friday.

Why It Matters

New trial data from Dyne Therapeutics on DYNE-101 could impact its stock performance and future funding, influencing investor sentiment and potential market opportunities in gene therapy.

Source: Benzinga
Market Sentiment: Negative
DYN stock latest news image
Quick Summary

Dyne plans to start a global expansion cohort of the ACHIEVE trial for DYNE-101 in DM1, aiming for U.S. Accelerated Approval submission in H1 2026 after positive study results.

Why It Matters

The initiation of a global Registrational Expansion Cohort for DYNE-101 indicates potential regulatory approval and market entry, which could significantly impact Dyne Therapeutics' stock value and future revenues.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About DYN Stock

What is Dyne Therapeutics Inc's (DYN) stock forecast for 2025?

Based on our analysis of 12 Wall Street analysts, Dyne Therapeutics Inc (DYN) has a median price target of $50.00. The highest price target is $66.00 and the lowest is $18.00.

Is DYN stock a good investment in 2025?

According to current analyst ratings, DYN has 11 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.91. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for DYN stock?

Wall Street analysts predict DYN stock could reach $50.00 in the next 12 months. This represents a 259.5% increase from the current price of $13.91. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Dyne Therapeutics Inc's business model?

The company operates as a biotechnology firm, focusing on developing a portfolio of therapeutics specifically for genetically driven muscle diseases. It generates revenue by advancing its clinical programs and potentially monetizing its therapeutic developments through partnerships, licensing agreements, or product sales once they receive regulatory approval.

What is the highest forecasted price for DYN Dyne Therapeutics Inc?

The highest price target for DYN is $66.00 from Paul Matteis at Stifel, which represents a 374.5% increase from the current price of $13.91.

What is the lowest forecasted price for DYN Dyne Therapeutics Inc?

The lowest price target for DYN is $18.00 from Tessa Romero at JP Morgan, which represents a 29.4% increase from the current price of $13.91.

What is the overall DYN consensus from analysts for Dyne Therapeutics Inc?

The overall analyst consensus for DYN is bullish. Out of 12 Wall Street analysts, 11 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $50.00.

How accurate are DYN stock price projections?

Stock price projections, including those for Dyne Therapeutics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.